Published clinical-trial data and ongoing studies continue to evaluate its safety profile, including gastrointestinal tolerability, heart-rate changes, pancreatic and gallbladder-related events, kidney-related risks in the setting of dehydration, and other potential adverse events
5 However, not all small-molecule GLP-1R agonists have advanced successfully
Additionally, there were more deaths in the Tirzepatide group than semaglutide (12 vs 1)
10.1016/j.neuron.2017.09.042 Neuron 42 Llewellyn-SmithI
At Centra Internal Medicine, patient safety and treatment effectiveness are our top prioritiesespecially when it comes to hormone therapies like testosterone replacement therapy (TRT)
Every moment at room temperature is a moment you're chipping away at the peptide's maximum shelf life